RevMed nears EU okay for pancreatic cancer drug Rasonque
Revolution Medicines is just weeks away from getting EU approval for its keenly anticipated oral RAS drug Rasonque for pancreatic cancer.
Newsletters and Deep Dive digital magazine
Revolution Medicines is just weeks away from getting EU approval for its keenly anticipated oral RAS drug Rasonque for pancreatic cancer.
The FDA has handed ImmunityBio a key label extension for bladder cancer therapy Anktiva, giving it a leg-up on rival drug Inlexzo from J&J.
August and September brought leadership changes across healthcare communications, consulting, investment, and industry organisations.
GSK is said to be preparing to cut around 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched by CEO Luke Miels.
Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign, according to the European Commission.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks